• Francesca Pagani, Claudia Testi, Alfonso Grimaldi, Giorgio Corsi, Barbara Cortese, Bernadette Basilico, Paola Baiocco, Simone De Panfilis, Davide Ragozzino, and Silvia Di Angelantonio.
• Center for Life Nanoscience, Istituto Italiano di Tecnologia, Rome, Italy; Nanotechnology Institute, CNR-Nanotechnology Institute, Sapienza University, Rome, Italy.
• Neuroscience. 2020 Jul 15; 439: 241-254.

AbstractDimethyl fumarate (DMF) is the only available approved drug for first line treatment of multiple sclerosis (MS), a lethal condition impairing central nervous system (CNS). To date, however, little is known of its mechanisms of action. Only recently, it has been suggested that DMF exerts neuroprotective effects acting as an immunomodulator and that it may alter the activation state of microglia cells, crucial in MS pathogenesis. However, DMF effects on microglia functions are still not well determined. Here, we examine the effects of DMF treatment on microglia functional activities, as phenotype, morphology, processes motility and rearrangement, migration, ATP response and iron uptake in mouse primary microglia culture and acute hippocampal slices. We found that DMF treatment reduces microglia motility, downregulating functional response to ATP, increases ferritin uptake and pushes microglia towards an anti-inflammatory phenotype, thus reducing its proinflammatory reactivity in response to tissue damage. These results highlight the effects of this compound on microglia functions and provide new insights on the mechanism of action of DMF in MS treatment.Copyright © 2019 IBRO. Published by Elsevier Ltd. All rights reserved.

16 keywords...

hide…